PFM Health Sciences’s Coherus Oncology CHRS Stock Holding History

PFM Health Sciences’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-62,400	Closed	-$895K	–	95
2017 Q2	$895K	Buy	+62,400	New	+$1.2M	0.02%	90

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

PFM Health Sciences's CHRS Position: Q3 2020 in Review

PFM Health Sciences sold out of Coherus Oncology (CHRS) in Q3 2020, closing a stake of 411,727 shares — an estimated $7.35M sold.

PFM Health Sciences first reported a position in CHRS in Q2 2015 and held it in 11 quarters. The position peaked at $32.2M in Q2 2019. 201 funds tracked by Wall St. Rank hold CHRS as of Q3 2020.

PFM Health Sciences reported no remaining Coherus Oncology position as of Q3 2020 after selling out during the quarter.
PFM Health Sciences sold 411,727 Coherus Oncology shares in Q3 2020, an estimated $7.35M.
PFM Health Sciences first reported a position in Coherus Oncology in Q2 2015 and held it in 11 quarters.
PFM Health Sciences's Coherus Oncology position peaked at $32.2M in Q2 2019.
201 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2020.

Based on PFM Health Sciences's 13F filing for Q3 2020, filed 16 Nov 2020.